1. Introduction {#s0005}
===============

Breast cancer is the most challenging type of cancer worldwide. In 2018, about 2.1 million new breast cancer cases have been diagnosed. In over 100 countries, it ranks as the leading causes of cancer death ([@b0030]). Estrogen receptors (ER) are responsible for approximately 70--75% of inter-tumor heterogeneic nature of breast cancer. Estrogens on binding to ER is responsible for the transcription/expression of many growth factors involving cellular proliferation ([@b0140]). Apart from estrogens, there are many non-steroidal growth factors including EGF and IGF1, that can bind to ER and stimulate proliferation via signal transduction pathways like MAPK pathway ([@b0085]). Progesterone receptor (PR) also plays an equal importance in cancer development and progression as ER.

The treatment regimens followed in ER+/PR+ breast cancer cases are mostly hormonal/endocrine therapy. It is done by blocking the ER, in-turn controlling the growth promoting effects on the cell. Though, it is recognized as an effective treatment for ER+/PR+ patients, most of the patience develops resistance to such therapies. There is a vital need for the novel therapies over the existing hormonal therapies, thereby extending the progression period, eliminating or reducing the resistance and postpone the chemotherapy ([@b0045]).

In accordance with this, our research group indulges in synthesis of novel small molecule drugs for multiple cancer treatments. One such phenolic derivatives is, 2-((1, 2, 3, 4-Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol (THMPP), found to have good cytotoxicity activity against bone carcinoma cells ([@b0080]). We hypothesize that THMPP might have anticancer activity against breast cancer and hence we wish to explore the mechanism of its action of the compound THMPP against breast cancer cells.

The present study also signifies that THMPP can induce cell death in breast cancer cells via EGFR signaling pathway. The EGFR overexpressed in metastatic breast cancer cells that influences the downstream signaling pathways such as the ERK MAPK, PI3K-AKT, SRC, PLC-γ1-PKC, JNK, and JAK-STAT pathways. The PI3K/AKT/mTOR pathway is the well-known signaling pathway involved in cell proliferation and survival. In tumorigenesis, this signal cascade is continuously activated even in the absence of any growth factors/ligands. Inhibition of this pathway can suppress the tumor growth and eventually benefit the ER+ patient through endocrine therapy ([@b0110]). Hence, we also propose to investigate the effect of THMPP in the regulation of PI3K signaling pathway genes in combination with computational analysis.

2. Materials and methods {#s0010}
========================

2.1. Cell lines and culture {#s0015}
---------------------------

Human breast adenocarcinoma cell lines, MCF-7, SkBr3; Triple negative breast cancer cells, MDAMB-231; and rat myoblast cells, H9C2, were obtained from NCCS, Pune. All the cell lines used in the study was EGFR (+). Cells were cultured in Dulbecco\'s Modified Eagle Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS), maintained at 37 °C humidified with 5% CO~2~ ([@b0155]). THMPP ([Fig. 1](#f0005){ref-type="fig"}a) was synthesized by our research group as previously described. Untreated cells were used as a negative control with cyclophosphamide, as a positive control ([Fig. 1](#f0005){ref-type="fig"}b). The characterization of the chemical compound and the preparation of THMPP was described in the previously established procedure ([@b0050], [@b0055]). NMR spectroscopic data of the compound was included as the supplementary file (Supplementary file 1).Fig. 1Cytotoxicity effect of THMPP in different breast cancer cell lines. (a) and (b)- Ligand structure: 2D structure of THMPP and CP. IUPAC: − 2-((1, 2, 3, 4-Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol and N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ^5^-oxazaphosphinan-2-amine, respectively; M. wt -- 329.443 and 261.083. The phase contrast microscopic images of MCF-7 cell line (c) untreated and (d) treated. Cell cytotoxicity of THMPP in different cell lines by MTT assay (e) MCF-7 cells (f) SkBr3 cells at different concentration (10 µM, 25 µM, 50 µM, 75 µM and 100 µM) and (g) Treatment of H9C2 cells with10µM and 100 µM of THMPP. Cyclophosphamide was used as a positive control; (h) Percentage of growth inhibition in multiple breast cancer cell lines and non-tumorous cells treated with 10 µM THMPP. Data points and error bars represent mean ± S.E.M (n = 3 per group). Statistical significance was assumed for p-values \*P \< 0.0001.

2.2. Cytotoxicity assay {#s0020}
-----------------------

The cytotoxicity potential of THMPP against the growth of breast cancer cells were analyzed using MTT assay ([@b0115]). The cell density of 1.2 × 10^4^ cells/well were plated in 96 well plates and maintained at 37 °C overnight. Cells were treated with varying concentrations of the samples (10, 25, 50, 75 and 100 µM) for 24 h, followed by the addition of 100 µl medium with 10 µl of MTT (5 mg/ml). As a comparative study, MDAMB-231 cells were also treated with 10 µM concentration of THMPP. H9C2, non-tumorous cells were used as a control cell line and treated with the lower concentration of 10 µM and higher concentration of 100 µM THMPP. The medium was discarded after 4 h of treatment and the formazan crystals was dissolved using 100 µl of DMSO. The purple color developed was read using microtiter plate reader at 570 nm. Cyclophosphamide was used as the positive control and the cells with the medium (untreated) serves as a control. Cell viability was calculated using the following formula:$$Viability\mspace{900mu}\% = \left( \frac{Test\mspace{900mu} OD}{Control\mspace{900mu} OD} \right) \times 100;\mspace{900mu} Cytotoxicity\mspace{900mu}\% = 100 - Viability\%.$$

2.3. Caspases 3 and 9 activity {#s0025}
------------------------------

Caspase-3 and -9 activities were measured by colorimetric assay kit, following the manufacturer's protocol (Calbiochem, Merck). Treated cells were lysed using the buffer containing 50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT, 100 mM EDTA and centrifuged at 10000 rpm for 1 min. The extracts were carefully collected, and the protein concentration was estimated by Bradford's assay. Approximately, 100--200 µg of protein for each assay was prepared by lysing the cell with 50 µl cell lysis buffer and incubated in 96-well plates with 5 µl of the 4 mM p-nitroanilide (pNA) substrates, DEVD-pNA for 2 h at 37 °C. The Caspase-3 and -9 activities were analysed by measuring the cleaved substrate to free pNA at 405 nm in a microplate reader. The relative level of Caspase-3 and -9 were quantified using the ratio of the absorbance of THMPP treated to untreated cells.

2.4. DNA fragmentation {#s0030}
----------------------

To study the effect of the compound in apoptosis induction in breast cancer cells, DNA of MCF-7 cells were subjected to electrophoresis. Briefly, MCF-7 cells were lysed using 100 µl of cell lysis buffer for one hour at room temperature, and the cell debris was removed by centrifugation for 15 min at 3000 rpm at 4° C. The supernatant was then mixed with equal volume of phenol: chloroform: isoamyl alcohol mixture, and then centrifuged at 5000 rpm for 15 min. The DNA was precipitated on adding 40 µl of 3.5 M ammonium acetate and ice-cold isopropanol to the aqueous phase and incubated at −20 °C for 1 h. The sample was centrifuged at 10000 rpm for 15 min and the pellet was washed with 70% ethanol and stored in 20--50 µl of TE buffer. DNA samples were electrophoresed at 50 V in 2% agarose gel (*w*/*v*). DNA was detected using EtBr staining under UV light along with DNA ladder (1 kb) as control ([@b0020]).

2.5. RNA extraction and CDNA synthesis {#s0035}
--------------------------------------

Total cellular RNA from both the untreated and treated MCF-7 cells were extracted using ONE STEP-RNA Reagent (Bio Basic Canada Inc.). This method is an improved version of single-step RNA isolation using phenol and guanidine isothiocyanate ([@b0035]). RNA pellet was extracted and vacuum dried for 5--10 min, dissolved in DEPC treated water and stored at −20 °C. The isolated RNA (1--2 µg) was immediately reverse transcribed using EasyScript Plus™ Reverse Transcriptase primed using oligo-dT. The reaction mixture consists of 1--2 µg of RNA, 2 µl oligo-dT (stock 10 µM), with the total volume of 12.5 µl with DEPC-treated water. The mixture was incubated at 65 °C for 5 min and 1X reverse transcriptase buffer, 2.5 mM of dNTP mix, and 40 U/µl of RNase inhibitor were added in specified order. Finally, 1 µl of Easy Script reverse transcriptase (200 U/µl) was added after 5 min of incubation at 42 °C. The final reaction was set up at 42 °C for 50 min, heated up to 70 °C for 10 min and chilled on ice ([@b0035]).

2.6. Reverse transcription polymerase chain reaction (RT-PCR) analysis {#s0040}
----------------------------------------------------------------------

Amplification of the target genes *EGFR*, *PI3K*, *S6K1* and β-actin were achieved using specific forward and reverse primers. β- actin, that shows the constitutive expression was used as a control for the gene expression analysis. The primers for the target mRNA were used as follows: *EGFR*, Fw: 5′- TCCCCGTAATTATGTGGTGACAGATC-3′ and Rv: 5′-ACCCCTAAATGCCACCGGC-3′ with the amplicon size 250 bp; *PI3K,* Fw: 5′-AACACAGAAGACCAATACTC-3′ and Rv: 5′-TTCGCCATCTACCACTAC-3′ with the amplicon size of 195 bp; *S6K1,* Fw: 5′-CACATAACCTGTGGTCTGTTGCTG-3′ and Rv: 5′- AGATGCAAAGCGAACTTGGGATA-3′ with the amplicon size of 180 bp; and for reference gene *β- actin,* Fw: 5′-CACCCGCGAGTACAACCTT-3′ and Rv: 5′-CCCATACCCACCATCACACC-3′ with the amplicon size of 204 bp, were synthesized and used further for PCR reactions.

The PCR reaction was setup using the following reagents: 1X Taq Buffer (with MgCl~2~), 0.2 mM dNTPs, 2.5 mM MgCl~2~, 0.3 µM forward and reverse primer, template cDNA (10% of the reaction) and 1U Taq Polymerase. Amplification was performed with the following PCR conditions: initial denaturation at 94˚ C for 2 min and 32 cycles of 94˚ C for 30 s, T~a~ for 1 min, 72˚ C for 1 min 20 s with the final extension at 72˚ C for 7 min. T~a~ was specifically optimized for each gene such as 56˚ C for *EGFR*, 54˚ C for *PI3K*, 56˚ C for *S6K1* and 54˚ C for β- actin. The amplicons were separated on 1.5% agarose gel with 100 bp ladder was as a marker at 50 V for 90 min. Image J software was used to quantify the band intensity.

2.7. FACS analysis {#s0045}
------------------

FACS analysis was performed to check the apoptotic induction in MCF-7 cells after treatment with THMPP using FITC Annexin V ([@b0160]). FITC Annexin V stained cells negative to propidium iodide (PI) represents apoptotic cells, FITC Annexin V/PI stained cells represents late apoptosis/ necrotic cells, whereas FITC Annexin V/PI negative cells represents live cells ([@b0090]). MCF-7 cells (1 × 10^5^ cells/sample) were treated with the IC~50~ concentration of THMPP and 5 µl of FITC Annexin V and 5 µl PI were added and then incubated for 15 min at 25° C in the dark. Binding buffer (1X) was added to each sample and subjected to flow cytometry analysis. The cells were acquired and gated by FITC-A and PE-A. All the measurements were performed within 1 h under similar settings in the equipment.

2.8. ACRIDINE orange/ethidium bromide (AO/ETBR) staining {#s0050}
--------------------------------------------------------

Apoptosis induction by THMPP in MCF-7 was identified by AO/EtBr dual staining. As explained previously, MCF-7 cells were treated with varying concentrations of THMPP, 78.23 µM, 83.23 µM and 88.23 µM with the control well left untreated. The cells were incubated for 24 h and trypsinised. It was centrifuged, and the pellet was suspended in PBS. To 25 μl of the supernatant solution, 25 μl of staining solution containing 1:1 mixture of 100 μg/ml AO and 100 μg/ml EB was added. The cell suspension (10 μl) was observed under fluorescent microscope using blue (420--495 nm) and green filter (510--560 nm) and at least 300 cells/well was used for quantification in different fields ([@b0015], [@b0040]).

2.9. Molecular docking using gold {#s0055}
---------------------------------

Automated docking for THMPP against EGFR was performed using the genetic algorithm GOLD (Version 3.2 CCDC, Cambridge, UK) ([@b0065]). It has been validated earlier with a data set containing 300 protein-ligand complexes retrieved from PDB ([@b0105]). To explore the ligand conformation and rotational flexibility of selected receptor, GOLD program makes use of genetic algorithm (GA). Grid box not exceeding 10 Å in size was chosen and the coordinates of the enclosing box (x = 121 Å; y = 87 Å; z = 45 Å) were also described from the active residues. Maximum of 10 different structural conformations for docking was examined and the highest binding conformers were selected for further analysis ([@b0120]).

2.10. QSAR analysis of THMPP {#s0060}
----------------------------

A quantitative structure-biological activity-property relationship (QSAR) approach was performed to quantitatively depict and provide mechanistic insights into interactions between the chemical structures of THMPP by considering the compounds with similar structures. QSAR is used for testing the relationship between the molecular descriptors of the set of compounds of interest with their respective biological activity ([@b0125]). Here, 32 compounds were selected which share a significant structural similarity with the THMPP. In addition, biological activity in terms of IC~50~ were also collected from the literature ([Table 1](#t0005){ref-type="table"}). The Dragon software calculates the descriptors for the compounds, which has about 1497 descriptors, that are classified into 18 groups. Each molecule in the training set were found to have set of 18 descriptors ([@b0150]). Set of descriptors that are most appropriate to the IC~50~ of the compounds were selected for further analysis, and the MLR models were built and QSAR equations eliminating the variables were established using BUILDQSAR software.Table 1List of training set and test set compounds with its IC~50~ values.Training SetS.NoCompound NameIC~50~References12-((1,2,3,4-tetrahydroquinolin-1-yl)(4-methoxyphenyl)methyl)phenol83.23Present Study2Curcusone B0.2[@bib163]3Curcusone C0.084Curcusone D0.15voruscarin46Uscharin472-Hydroxy-isojatrogrossidion0.282-epi-hydroxyisojatrogrossidion0.29Multidione5.5104Z jatrogrossidentadion0.6114E jatrogrossidentadion2.112Pinostrobin10.213Balanitin-6/72.614Jatropholone7.515Multi-substituent phenyl derivatives 11.38[@bib164]16Multi-substituent phenyl derivatives 411.7417Mangrove-derived quinones 70.1718Mangrove-derived quinones 82.5319Mangrove-derived quinones 91.4320Mangrove-derived quinones 1113.2321Mangrove-derived quinones 1316.32  Test SetS.NoCompound NameIC~50~References1Mangrove-derived quinones 1435.23[@bib164]2Mangrove-derived quinones 1817.223Isoflavone analog 7819.774Fatty acid derivatives 810.415Phytol34[@bib162]6phenolic constituents 462.9[@bib161]7phenolic constituents 663.8

2.11. ADMET analysis {#s0065}
--------------------

The various pharmacokinetics properties and physiochemical properties of the compound, THMPP were calculated using ADMET descriptors. ADMET can provide metabolic interactions of the drug by profiling its Absorption, Distribution, Metabolism, Excretion and Toxicity properties. The prediction will contain the following important ADMET descriptors such as Blood-Brain Barrier penetration, Human Intestinal Absorption, CYP450 2C9, Caco-2 cell permeability and Ames test. The drug likeliness score of the compound determines the potentiality of the compound.

3. Results {#s0070}
==========

3.1. THMPP induced cytotoxicity effect {#s0075}
--------------------------------------

To evaluate the effect of THMPP against the human breast cancer cell lines MCF-7 and SkBr3 and the non-cancerous mouse myoblast cells H9C2, the percentage of cell proliferation/cell viability was measured using MTT assay. The phase contrast microscopic images of the treated and untreated MCF-7 cells are represented in [Fig. 1](#f0005){ref-type="fig"}c and d. THMPP showed a dose-dependent increase in the cytotoxicity against MCF-7 cells and SkBr3 ([Fig. 1](#f0005){ref-type="fig"}e and f). The toxicity of THMPP against MCF-7 and SkBr3 cells was found to be 36.47%, 53.98% and 18.86%, 40.47% at 10 μM and 100 μM, respectively. The IC~50~ concentration of THMPP against was less in MCF-7 with 83.23 µM than SkB3 cells with 113.94 µM ([Fig. 1](#f0005){ref-type="fig"}e and f). Cyclophosphamide was used as a positive control, where its cytotoxicity against MCF-7 and SkBr3 was significantly high. The IC~50~ value of CP against MCF-7 and SkBr3 was found to be 42.79 µM and 38.34 µM, respectively ([Fig. 1](#f0005){ref-type="fig"}e and f). Also, THMPP has least percentage of cytotoxicity to non-cancerous cells, H9C2 (0.91%) when compared with other breast cancer cell lines such as MCF-7(36%), SkBr3(18%) and MDAMB-231(30%) upon treatment with 10 µM of THMPP ([Fig. 1](#f0005){ref-type="fig"}g and h). These results suggested that THMPP has the ability to specifically target breast cancer cell lines than the normal cells. The differences in the treated conditions was found to be statistically significant as per two-way ANOVA (P-value \< 0.0001).

3.2. Caspase-3 and caspase-9 induction {#s0080}
--------------------------------------

To clarify whether THMPP could induce apoptosis, caspase-3 and -9 activities were measured in MCF-7 and SkBr3. The cells were treated with the respective IC~50~ concentration of THMPP. In both the cell lines, there was significant fold change in the enzyme activity after the treatment. In MCF-7 cells, it was found that the caspase-3 and -9 activities were increased by a fold level of 0.17 and 0.47, whereas in SkBr3, fold change of 0.07 and 0.25 was observed respectively, when compared to the untreated cells ([Fig. 2](#f0010){ref-type="fig"}a and b). Thus, THMPP could activate caspase enzyme activity, thereby induces apoptosis in both the cell lines. The values were statistically significant, as per two-way ANOVA test (P \< 0.0001).Fig. 2Caspase-3 and Caspase-9 activity in THMPP treated MCF-7 and SkBr3 cell lines. (a) Relative caspase-3 activity of THMPP treated MCF-7 and SkBr3 compared with the untreated cells. The results were considered significant (two way ANOVA) in comparison with the untreated group (\*, P ≤ 0.007). (b) Relative caspase-9 activity of THMPP treated MCF-7 and SkBr3 compared with the untreated cells. The results were considered significant (two way ANOVA) in comparison with the untreated group (\*, P \< 0.0001). Data represents Mean ± SEM (n = 3 experiment).

3.3. Induction of DNA strand break by THMPP {#s0085}
-------------------------------------------

To further substantiate the ability of THMPP in inducing apoptosis, the cells were subjected for DNA fragmentation assay. The DNA fragmentation is a sign of apoptosis, which causes nicks in genomic DNA of the cells (Eastman and Barry, 1992). The genomic DNA from THMPP treated MCF-7 cells was isolated and analysed by agarose gel electrophoresis. The result shows that untreated cells have intact DNA with no laddering whereas treated cells showed a characteristic ladder of inter-nucleosomal fragmentation, confirming the induction of apoptosis ([Fig. 3](#f0015){ref-type="fig"}a).Fig. 3DNA fragmentation of MCF-7 cells exposed to THMPP (a) DNA gel electrophoresis of internucleosomal DNA fragmentation in 1.5% Agarose gel upon treatment with THMPP in MCF-7 cell lines (lane 1) Marker-1 Kb ladder; (lane 2) negative control without treatment; (lane 3) DNA of cells treated with THMPP. Assessment of apoptosis by FACS of apoptosis in THMPP (IC~50~ − 83.23 µM) treated MCF-7 cells measured using FITC-labelled annexin V/PI (b) untreated cells; (c) THMPP treated MCF-7 cells. UL- necrotic cells, UR- late apoptotic cells, LL - viable cells, LR -- early apoptotic cells. (d) Quantitative analysis on the percentage of viable, apoptotic, or necrotic cells by FACS analysis.

3.4. Analysis of apoptosis induction by THMPP using Annexin V/PI {#s0090}
----------------------------------------------------------------

The phosphatidylserine externalization in MCF-7 cells stained with Annexin V-FITC/PI was quantified by flow cytometry to assess the apoptotic cell death. The analysis showed that THMPP could induce apoptosis in a concentration-dependent manner ([Fig. 3](#f0015){ref-type="fig"}). The untreated cells were mostly viable. The cells with compromised membrane were analysed by staining using membrane impermeable dye, PI. Thus the counter staining with PI and Annexin V delineates the cells at different cell phase. The cells treated with THMPP showed 3.21% of early apoptotic cells, 36.02% of late apoptotic cells and 59.7% viable cells ([Fig. 3](#f0015){ref-type="fig"}d). This substantiates the effect of THMPP in apoptosis mediated cell death ([Fig. 3](#f0015){ref-type="fig"}b and c).

MCF-7 cells were treated with a varying doses of THMPP for 24 h, as described in the method section. Apoptotic cell death causing nuclear fragmentation was assessed upon treatment with varying concentration of THMPP and the cells were observed under flourescent microscope ([Fig. 4](#f0020){ref-type="fig"}). The dual AO/EB fluorescent staining qualitatively and quantitatively reveals the morphological changes in apoptotic cells, with clear distinction between normal cells, apoptotic cells, and necrotic cells.Fig. 4Fluorescence microscopy images of AO-EtBr stained MCF-7 cells after treatment with THMPP. (a) Untreated cells; MCF-7 cells treated with THMPP at different concentrations (b) 78.23 µM, (c) 83.23 µM and (d) 88.23 µM. The white, yellow and blue arrows are representing viable, early apoptotic, and late apoptotic cells respectively. (e) percentage of apoptosis at different concentrations, where treatment 1 is 78.23 µM; treatment 2 is 83.23 µM; and treatment 3 is 88.23 µM.

The [Fig. 4](#f0020){ref-type="fig"}a--d showed the mode of cell death by dual AO/EB staining. Control cells (untreated MCF-7 cells) are normal healthy cells with green fluorescent cells having normal cytoplasm and nuclei morphology, and represents only less than 2% cells in apoptotic stage. The cells entering early apoptosis appears yellowish green fluorescence with membrane blebbing and those cells in late apoptosis appeared orange/red fluorescence. It is observed that 48% of the cells were in apoptotic stage upon treatment with 83.23 µM of THMPP, 61% cells at 88.23 µM and 32% cells at 78.23 µM of THMPP treatment. As the concentration of the compound increases, there is a significant increase in the apoptosis induction and thus THMPP induces cell death through apoptosis pathway ([Fig. 4](#f0020){ref-type="fig"}e).

3.5. Effect of THMPP on the expression of *PI3K* and *S6K1* genes {#s0095}
-----------------------------------------------------------------

To further understand the mechanism of action of THMPP, we examined the influence of THMPP in PI3K signaling pathway. Semi-quantitative RT-PCR was carried out using primers specific for *EGFR, PI3K and S6K1* genes with β-actin as the reference control. The genes with respective band size of 204 bp (β*-actin*), 250 bp (*EGFR*), 195 bp (*PI3K*) and 180 bp (*S6K1*) were observed clearly in agarose gel ([Fig. 5](#f0025){ref-type="fig"}a). The ImageJ was used to calculate the expression fold of each gene. EGFR gene expression was not altered upon THMPP treatment when compared with the untreated cell lines. But, there occurs a reduced level of altered gene expression level with 0.5 fold change in both *PI3K* and *S6K1* ([Fig. 5](#f0025){ref-type="fig"}b). These results suggest that the THMPP could induce apoptosis by down regulating the expression of genes, *PI3K* and *S6KI* involved in PI3K/AKT signalling pathway ([Fig. 5](#f0025){ref-type="fig"}b). The values were found to be statistically significant, as per two way ANOVA test (P-value \< 0.0001).Fig. 5Gene expression analysis in MCF-7 cell upon THMPP treatment. (a) RT-PCR amplification of *β- actin* (204 bp), *EGFR* (250 bp), *P13K* (195 bp) and *S6K1* genes (180 bp). (Lane 1: 100 bp DNA marker, Lane 2: control (untreated) Lane 3: (PCR amplicon treated with THMPP); (b) Optical density was measured to evaluate the mRNA expression of *EGFR; S6K1; PI3K*, with the housekeeping gene *β-actin* serving as the normalization control. The fold change represented as the expression ratio of the genes. Data points and error bars represent mean ± S.E.M (n = 3 per group). Statistical significance was assumed for p-values \*P \< 0.0001. (c) Molecular docking analysis of THMPP with EGFR. The surface-docking model of THMPP in the EGFR active site. The ligand is represented as sticks; and the protein active sites as lines, hydrogen bond interaction are shown in dotted lines (Red) and the interacting residues are labelled.

3.6. Molecular docking of THMPP with EGFR {#s0100}
-----------------------------------------

Molecular docking was performed using GOLD ([@b0065]). The 3D structure of EGFR was availed from protein data bank with the PDB ids: 2RGP. Binding compatibility was evaluated based on the docked energy in kcal/mol ([Fig. 5](#f0025){ref-type="fig"}c). The active sites present in the crystal structure of the five receptors were obtained from the pdbsum database which was further used for the docking analysis. The following amino acids are present in the 32 active sites of EGFR receptors, ie., Leu718, Gly719, Ala722, Val726, Ala743, Lys745, Met766, Cys775, Arg776, Leu777, Leu788, Thr790, Gln791, Leu792, Met793, Pro794, Phe795, Gly796, Asp800, Arg803, Arg832, Leu833, Val834, His835, Arg836, Asp837, Leu844, Leu862, His888, Lys913, Lys970, Arg977. Many significant interactions were predicted between the ligand (THMPP) and the receptor (EGFR). The best docking score of 33.02 determines the best interaction. The [Fig. 5](#f0025){ref-type="fig"}c represents the docking score and residual values of the interaction.

3.7. THMPP structure activity relationship and its pharmacokinetics properties {#s0105}
------------------------------------------------------------------------------

BUILDQSAR was used to predict the anti-cancer potential of the compound, THMPP. Based on the compounds selected ([Table 1](#t0005){ref-type="table"}), a QSAR model was built. The regression line was plotted and the compounds that significantly deviate away were considered as outliers and excluded from the modelling procedure. The QSAR model was tested against the compounds in the test set and the predictability of the QSAR model was validated ([Fig. 6](#f0030){ref-type="fig"}) using the correlation coefficient value, (r) 0.970 for training set ([Fig. 6](#f0030){ref-type="fig"}a) and 0.985 for the test set ([Fig. 6](#f0030){ref-type="fig"}b). This shows the efficiency of the model generated and the results clearly indicated that the compound was predicted to be a potent anti-cancer agent. In particular, THMPP correlates well with the equation, which substantiates its toxic effect against cancer cells.Fig. 6QSAR Correlation plot. (a) Training set correlation coefficient (R2 = 0.970). (b) Test set correlation coefficient (R2 = 0.985).

Further, the results of the ADMET analysis are shown in the [Table 2](#t0010){ref-type="table"}. The oral bioavailability and ADMET risk profiling were within their acceptable limit for THMPP. It obeyed Lipinski rule of five and had good absorption properties. Also, it is predicted to cross the Blood Brain Barrier and has Caco-2 permeability and good intestinal absorption and predicted to be localized in mitochondria of the cell. The metabolism and toxicity parameters are also acceptable for THMPP. The complete endpoints prediction concludes that the compound THMPP, exhibits good drug likeliness properties.Table 2ADME and drug likeness properties of the ligand THMPP.End PointsHTS DataAccuracyBlood-Brain BarrierBBB+0,8003Human Intestinal AbsorptionHIA+0,9971Caco-2 PermeabilityCaco2+0,5375P-glycoprotein SubstrateNon-substrate0,7583P-glycoprotein InhibitorNon-inhibitor0,6068Non-inhibitor0,9278Renal Organic Cation TransporterNon-inhibitor0,8148Subcellular localizationMitochondria0,6819CYP450 2C9 SubstrateNon-substrate0,6246CYP450 2D6 SubstrateNon-substrate0,8092CYP450 3A4 SubstrateSubstrate0,6311CYP450 1A2 InhibitorInhibitor0,7358CYP450 2C9 InhibitorInhibitor0,651CYP450 2D6 InhibitorNon-inhibitor0,8645CYP450 2C19 InhibitorNon-inhibitor0,5508CYP450 3A4 InhibitorNon-inhibitor0,7413CYP Inhibitory PromiscuityHigh CYP Inhibitory Promiscuity0,7253Human Ether-a-go-go-Related Gene InhibitionStrong inhibitor0,5167Non-inhibitor0,7336AMES ToxicityAMES toxic0,9402CarcinogensNon-carcinogens0,6772Fish ToxicityHigh FHMT0,9583Tetrahymena Pyriformis ToxicityHigh TPT0,9846Honey Bee ToxicityLow HBT0,513BiodegradationNot ready biodegradable0,9604Acute Oral ToxicityCategory III0,7048Carcinogenicity (Three-class)Warning0,4551

4. Discussion {#s0110}
=============

Several studies are reported on various natural and synthetic phenolics to have cytotoxic effect on cancer cells. ([@b0095], [@b0100], [@b0130]). Reports on phenolic derivative like phenolic acids are available which deal with anti-oxidant property and their action on cancer cell proliferation. Many dietry phenolic acids have also been tested. In particular, the well known phenolics, caffeic acid when treated with breast cancer cells, T47D showed good growth inhibition with the IC~50~ of 2.17 × 10^−9^ M ([@b0075]). Phenolic compounds which are structurally related have been also shown to induce cell cycle arrest and apoptosis of cancer cells([@b0005]) ([@b0010]).

The susceptible nature of tumor cells to apoptosis is the vital determinant of chemotherapy efficacy ([@b0135]). Thus, an effective anti-cancer drugs, which can target breast cancer cells by inducing apoptosis is needed for efficient treatment. We determined the ability of THMPP to induce apoptosis in breast cancer cells using DNA fragmentation analysis, Caspase3/9 activity assay, FITC/Annexin staining and AO/EtBr fluorescent staining procedures. It is evident that, THMPP induced apoptosis via caspase 3/9 activation, but then other signaling pathways might also be induced along with caspase 3/9 activation. Therefore, further analysis of apoptosis and/or autophagy signaling pathway on multiple cancer cell types should be implemented for anticancer development.

On the other hand, expression of genes involved in the tumor progression is altered in cancer conditions. PI3K/AKT/S6K1/mTOR pathway promotes cell survival and cell proliferation, which is continuously over-expressed in breast cancer cells. In this study, the newly synthesized THMPP was able to down regulate *PI3K* and *S6K1* genes, which could suppress proliferation and induce apoptosis. Also, decrease in the *S6K1* expression reduces the risk of radiation resistance of cancer cells([@b0145]). This attribute reduces the risk of side effects which are common in chemotherapeutic agents. Similar researches were also carried out in the well known polyphenols of green and black tea and were reported to have anti-cancer properties by up- or down-regulating a number of key enzymes ([@b0025]). Overall, THMPP was identified to be a candidate drug to treat multiple breast cancer and further clinical trials in animal model is essential to verify the antitumor activity.

5. Conclusion {#s0115}
=============

The present investigation revealed that THMPP can act as a potential drug for treating breast cancer. This study demonstrated that THMPP has cytotoxic activity on MCF-7 and SkBr3 breast cancer cell line. THMPP was determined to be apoptosis induced, triggering DNA fragmentation as well as caspase 3/9 in human breast cancer cell lines. Additionally, molecular docking of THMPP with EGFR identified that the can potentially interact with EGFR and activate its downstream signaling pathway. Gene expression analysis also confirms the downregulation of *PI3K*, suggesting that THMPP might de-regulate the EGFR signaling pathway in breast cancer cells. The QSAR and ADMET analysis also proves that THMPP as non carcinogenic and a good drug-like candidate for breast cancer treatment. Overall, we anticipate that THMPP can be technically exploited further for the development of an effective anti-breast cancer agents.
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